Porcine circovirus vaccine veterinary-grade API enters downstream processing as a thermolabile biological material requiring route-specific formulation. Cold-chain storage is maintained at 2–8 °C for liquid antigen and at ≤-20 °C for frozen bulk unless product-specific stability data indicate otherwise. Processing areas for parenteral presentations are operated under ISO 14644-1 Class A/B cleanroom conditions; non-sterile oral presentations are controlled to Ph. Eur. 5.1.4 microbial limits. The physical format of the API—liquid concentrate, frozen suspension, or lyophilised powder—dictates the first downstream unit operation, but subsequent steps must preserve capsid integrity, antigen binding, and batch potency as measured by ELISA, virus neutralisation, or immunoperoxidase monolayer assay. Because this is a biological API rather than a chemical drug substance, unit operations are constrained primarily by thermal lability and shear sensitivity rather than chemical compatibility alone.

Antigen particle size and aggregation state are assessed by dynamic light scattering before and after high-risk steps. Low-shear impeller mixing at 50–150 rpm is used for adjuvanted suspensions; rotor-stator homogenisation is avoided because high shear above 10,000 s⁻¹ can dissociate antigen-adjuvant complexes or create subvisible aggregates. Temperature excursions above 8 °C require product-specific thermal stability data; a cumulative excursion limit of 72 h below 15 °C is applied only where supporting stability data exist. Each downstream process should include in-process antigen quantification against the manufacturer’s reference standard to distinguish process loss from analytical interference caused by feed-matrix components, excipient lipids, or adjuvant particles.

Aqueous Injectable Suspensions and the Limits of Terminal Sterilisation

Terminal sterilisation by saturated steam at 121 °C for 15 min is incompatible with the antigen and is therefore replaced by aseptic processing. The compounding vessel is a 316L stainless-steel jacketed tank with a bottom-mounted magnetic impeller. Water for injection is cooled to 15–25 °C before antigen addition; aluminium hydroxide adjuvant is added to a final aluminium concentration of 0.1–0.5 mg/mL. If a carbomer adjuvant is used, it is pre-neutralised with sodium hydroxide to pH 7.0–7.4 before antigen loading. Final pH is adjusted with 0.1 M hydrochloric acid or sodium hydroxide; osmolality is maintained at 280–320 mOsm/kg with sodium chloride. The suspension is held for 30–45 min before sterile filtration or aseptic transfer to allow adjuvant-antigen interaction to stabilise.

Filtration strategy depends on particle size. Unadjuvanted antigen with a measured d₉₀ below 0.22 µm can be passed through a polyethersulfone membrane at ≤2 bar; adjuvanted formulations containing aluminium hydroxide or polymeric particles cannot be sterile-filtered without removing the adjuvant phase. In that case the adjuvant is sterilised separately by autoclaving and the antigen solution is filtered aseptically before the two phases are combined. Filling is performed in ISO 14644-1 Class A laminar flow using a peristaltic pump and single-use tubing; fill volume is controlled gravimetrically at ±2%. The final suspension is tested for sterility by Ph. Eur. 2.6.1, bacterial endotoxins by Ph. Eur. 2.6.14, visible and subvisible particles by Ph. Eur. 2.9.19 and Ph. Eur. 2.9.20, and antigen identity by ELISA. Aluminium content is confirmed by atomic absorption spectrometry if an adjuvant is present. Operational boundaries include avoidance of freeze-thaw cycles; frozen storage can lead to aluminium gel aggregation and potency loss in the presence of crystalline ice damage.

Lyophilised powders are selected when liquid injectable stability is insufficient at 2–8 °C or when distribution to tropical regions requires reduced cold-chain dependency. The liquid formulation containing antigen and lyoprotectant is filled into moulded or tubing glass vials and loaded onto lyophiliser shelves pre-cooled to -40 °C to -45 °C. Trehalose or sucrose at 2–5% w/v is used as a lyoprotectant; mannitol may be added as a bulking agent at 2–4% w/v to improve cake structure. Primary drying is performed at a chamber pressure of 0.05–0.15 mbar with shelf temperature gradually increased from -25 °C to 0 °C. Secondary drying at 20–25 °C for 4–8 h reduces residual moisture to ≤3.0% by Karl Fischer titration. Reconstitution behaviour is a process consistency indicator. The dried cake should reconstitute in water for injection within 60 s without visible particles; subvisible testing is performed by light obscuration according to Ph. Eur. 2.9.19. Reconstituted potency should not decline by more than 0.5 log₁₀ compared with pre-lyophilisation antigen titre. Batch-to-batch variation in cake appearance can be caused by inconsistent freezing rate; forced nucleation units or controlled ramp freezing reduce this variance on production lyophilisers. The residual moisture limit should be product-specific and confirmed by long-term stability; a generic ≤3.0% threshold may be too high for highly titre-sensitive antigen batches. Published data for this specific antigen-laden matrix is limited, so lyophilisation cycle development must include freeze-drying microscopy to determine collapse temperature and collapse duration.

What Happens When Tablet Compression Is Applied to Antigen-Loaded Granules?

Oral tablet development for porcine circovirus antigen is constrained by low antigen loading, heat sensitivity, and the absence of a harmonised potency release model. Published data for this specific configuration is limited; manufacturing feasibility is therefore assessed independently from immunological outcome. Direct compression is unsuitable because the antigen concentrate is cohesive and concentration heterogeneity can exceed ±10% at small scale. Wet granulation with povidone K30 at 2–5% w/w in a high-shear granulator or fluid-bed top-spray system binds antigen-coated excipients into sufficiently dense granules. Drying must keep product temperature below 45 °C; inlet air temperature is set at 50–60 °C and outlet air at 28–35 °C. Granule moisture is held below 3.0% before compression.

Compression is performed on a rotary tablet press at 5–15 kN compression force; tablet hardness is maintained between 30 N and 70 N. Excipients include mannitol, microcrystalline cellulose, crospovidone, and magnesium stearate; lubricant blending is limited to 3–5 min to avoid over-lubrication and delayed disintegration. Disintegration and dissolution are tested by Ph. Eur. 2.9.1 and Ph. Eur. 2.9.3, but these pharmacopoeial tests do not establish antigen release. Antigen-specific release in simulated gastric fluid and simulated intestinal fluid is measured by ELISA; matrix interference must be controlled with a placebo spike recovery of 70–130%. If gastric acid exposure must be avoided, an enteric film coat of methacrylic acid–ethyl acrylate copolymer is applied; dissolution in 0.1 M hydrochloric acid for 2 h should release no more than 10% antigen, followed by release at pH 6.8. These tablets remain experimental because no harmonised oral porcine circovirus potency standard is available and the correlation between tablet antigen release and mucosal protection has not been established in registered studies.

Enteric-coated capsules for antigen delivery to the distal small intestine are filled with antigen-loaded pellets or a lyophilised powder blend. A size 3 or 4 hard capsule is used for piglet oral dosing; fill mass is adjusted to 80–250 mg depending on antigen titre. Pelletised material is produced by extrusion-spheronisation or powder layering on inert non-pareil beads; the process uses a Wurster fluid-bed coater with inlet air at 45–55 °C and product temperature below 40 °C. The enteric coat is applied as an aqueous methacrylic acid copolymer dispersion to achieve a weight gain of 8–12%; coating thickness is monitored by scanning electron microscopy and dissolution in 0.1 M hydrochloric acid for 2 h, followed by phosphate buffer pH 6.8. Capsule content uniformity is assessed by Ph. Eur. 2.9.40; antigen content is measured by ELISA and requires a relative standard deviation below 5%. Liquid antigen concentrate cannot be directly filled into hard capsules unless it is first adsorbed onto silicified microcrystalline cellulose or beta-cyclodextrin; the adsorption capacity should not be exceeded because excess liquid will soften the capsule shell. The capsule presentation is not a substitute for injectable vaccination in registered herd health programmes; its application is limited to experimental mucosal administration and controlled challenge studies. Stability of the enteric coat under tropical humidity above 60% RH must be confirmed before field use.

Bulk Powder Sachet Filling and Antigen Recovery Limits

Bulk oral powder is prepared when the dose is to be dispersed into liquid feed, milk replacer, or drinking water at the point of use. The antigen is first spray-dried or lyophilised onto a protective matrix; trehalose, skimmed milk powder, or sodium caseinate at 5–10% w/w is used to stabilise the antigen during subsequent handling. Powder blending is performed in a bin blender or V-blender filled to 40–65% of working volume; mixing time is established by sampling at 5, 10, and 15 min. Antigen content uniformity is measured by ELISA on 10 locations; a relative standard deviation above 5% requires re-blending or geometric pre-dilution. Sachet filling is performed on a vertical form-fill-seal line with gravimetric checkweighing; fill mass tolerance is ±5% for powders above 1 g. Moisture ingress is the main failure mode. Sachet film must provide a water vapour transmission rate below 0.5 g/m²/24 h at 38 °C/90% RH according to ASTM F1249; desiccant pouches are added if the powder is hygroscopic. The powder is stored at 2–8 °C or ≤25 °C depending on the stability programme; storage below 0 °C may cause phase separation if liquid concentrates are spray-congealed rather than lyophilised. Reconstitution of bulk powder should be done in potable water free of chlorine or oxidative sanitisers; residual chlorine above 0.5 ppm can denature antigen. The powder is not sterile, and it must not be introduced into injectable lines or mixed with parenteral diluents without a sterilising-grade filtration step and bioburden assessment.

Granulation for feed top-dressing differs from powder blending because the particle-size distribution must match the final feed carrier rather than the sachet fill line. The granulation step uses a top-spray fluid-bed granulator; antigen is dissolved or suspended in a binder solution containing hydroxypropyl methylcellulose at 1–3% w/w and sprayed onto a carrier such as lactose monohydrate or maize starch. Inlet air temperature is 50–60 °C, product temperature 30–35 °C, and spray rate is adjusted so atomisation pressure does not exceed 1.5 bar. Dried granules are screened to 150–500 µm; oversized material is milled with a conical screen mill and undersized fines are recycled to the granulation feed. Segregation is controlled by matching particle size distribution of the antigen granules to the carrier feed particles. If the feed meal has a d₅₀ near 300 µm, the antigen granules should not have a d₅₀ below 200 µm or above 500 µm; otherwise percolation or top-floating may occur in the feed mixer. Blend uniformity is tested by taking 10 samples per batch and analysing antigen content by ELISA; relative standard deviation above 5% indicates insufficient mixing. The inclusion rate must be validated for each feed formulation because matrix effects from soybean meal, phytase, and organic acids can reduce antigen recovery in the analytical assay.

When a Silica-Based Carrier Is Used for Premix Antigen Blending

Premix presentation is used to dilute the API into a free-flowing carrier that can be mixed at 0.5–5 kg per tonne of final feed. Fumed silica or precipitated silica is used at 0.5–2% w/w to adsorb liquid antigen concentrate; the adsorption step is performed in a paddle mixer or planetary mixer at 30–60 rpm until the liquid is fully absorbed and the blend remains free-flowing. The first dilution is then extended by geometric addition of calcium carbonate or ground maize to a total premix batch size. A V-blender or double-cone blender filled to 40–65% of working volume is operated for 10–15 min; extended mixing beyond this window can cause electrostatic adhesion and loss of blend uniformity. Premix homogeneity is evaluated by the sampling plan in ISO 6497 where applicable; antigen-specific ELISA is performed in triplicate on each of 10 sample points. Moisture content of the premix is maintained below 5.0% to prevent microbial growth and antigen degradation; storage is in sealed aluminium-lined bags at ≤25 °C. The premix is not suitable for injection or direct oral drenching unless the feed-grade carrier matrix is fully dissolved and filtered; carrier particles can introduce pyrogen burden if diverted to parenteral routes.

Oral drench solutions and water-proportioner stocks are prepared by dissolving or suspending the API in a buffered vehicle. A citrate-phosphate buffer at 20–50 mM and pH 6.8–7.4 is used; tonicity agents such as sodium chloride or glycerol are added only if the solution will be administered to neonatal piglets with immature osmoregulation. The solution is passed through a 75 µm inline strainer before filling into polyethylene terephthalate or high-density polyethylene bottles; non-sterile solutions are tested for total aerobic microbial count and total yeast/mould count according to Ph. Eur. 5.1.4. A stock solution intended for proportioner dilution at 1:100 is verified for pH, visible clarity, antigen titre by ELISA, and preservative concentration if an antimicrobial agent is included. The buffered solution is held at 2–8 °C; repeated freeze-thaw cycles are avoided because antigen aggregation can occur at ice-liquid interfaces. If the solution is used through a water medicator, the dilution ratio must be validated at the target water flow rate because turbulent mixing and backpressure can alter antigen distribution in the drinking line.